HK1038881A1 - 通過共同給予前列腺素抑制劑增强抗體-細胞因子融合蛋白介導的免疫應答 - Google Patents

通過共同給予前列腺素抑制劑增强抗體-細胞因子融合蛋白介導的免疫應答

Info

Publication number
HK1038881A1
HK1038881A1 HK02100430.6A HK02100430A HK1038881A1 HK 1038881 A1 HK1038881 A1 HK 1038881A1 HK 02100430 A HK02100430 A HK 02100430A HK 1038881 A1 HK1038881 A1 HK 1038881A1
Authority
HK
Hong Kong
Prior art keywords
enhancement
antibody
administration
fusion protein
immune responses
Prior art date
Application number
HK02100430.6A
Other languages
English (en)
Inventor
S‧D‧吉利斯
Original Assignee
利思進藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 利思進藥品公司 filed Critical 利思進藥品公司
Publication of HK1038881A1 publication Critical patent/HK1038881A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HK02100430.6A 1998-04-17 2002-01-18 通過共同給予前列腺素抑制劑增强抗體-細胞因子融合蛋白介導的免疫應答 HK1038881A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8216698P 1998-04-17 1998-04-17
PCT/US1999/008376 WO1999053958A2 (en) 1998-04-17 1999-04-16 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor

Publications (1)

Publication Number Publication Date
HK1038881A1 true HK1038881A1 (zh) 2002-04-04

Family

ID=22169464

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100430.6A HK1038881A1 (zh) 1998-04-17 2002-01-18 通過共同給予前列腺素抑制劑增强抗體-細胞因子融合蛋白介導的免疫應答

Country Status (16)

Country Link
US (1) US20040033210A1 (zh)
EP (1) EP1071469A2 (zh)
JP (1) JP2002512204A (zh)
CN (1) CN1305387A (zh)
AU (1) AU758851B2 (zh)
BR (1) BR9909677A (zh)
CA (1) CA2328081A1 (zh)
CZ (1) CZ20003817A3 (zh)
HK (1) HK1038881A1 (zh)
HU (1) HUP0101343A3 (zh)
MX (1) MXPA00010151A (zh)
NO (1) NO20005186L (zh)
PL (1) PL343486A1 (zh)
RU (1) RU2217168C2 (zh)
WO (1) WO1999053958A2 (zh)
ZA (1) ZA200005477B (zh)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
HUP0103329A3 (en) * 1998-08-25 2003-09-29 Lexigen Pharmaceuticals Corp L Expression and export of angiostatin and endostatin as immunofusis
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001007914A1 (en) * 1999-07-26 2001-02-01 Childrens Hospital Los Angeles Research Institute Fenretinide increases antibody cellular toxicity
DK1200479T3 (da) * 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
DK1294401T3 (da) * 2000-06-29 2007-10-08 Merck Patent Gmbh Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
HUE032238T2 (en) * 2002-03-15 2017-09-28 Univ North Carolina Chapel Hill Primitive and proximal liver stem cells
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
RU2369616C2 (ru) 2003-12-30 2009-10-10 Мерк Патент Гмбх Слитые белки il-7
AU2004309063B2 (en) * 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005066348A2 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CA2591297C (en) * 2004-12-09 2015-01-13 Stephen D. Gillies Il-7 variants with reduced immunogenicity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
PL1966238T3 (pl) * 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
CN101351477B (zh) 2005-12-30 2011-11-16 默克专利有限公司 具有降低的免疫原性的抗cd19抗体
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
DE3812605A1 (de) * 1988-04-15 1990-06-07 Leskovar Peter Dipl Ing Dr Hab Immunregulative stoffe und stoffgemische zur aktiven beeinflussung des krankheitsverlaufes
ATE218889T1 (de) * 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
ATE208633T1 (de) * 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
WO1998000127A1 (en) * 1996-07-02 1998-01-08 Bar-Ilan University Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases

Also Published As

Publication number Publication date
CA2328081A1 (en) 1999-10-28
BR9909677A (pt) 2000-12-19
MXPA00010151A (es) 2002-08-06
HUP0101343A3 (en) 2003-10-28
WO1999053958A2 (en) 1999-10-28
WO1999053958A3 (en) 1999-12-02
CN1305387A (zh) 2001-07-25
PL343486A1 (en) 2001-08-27
HUP0101343A2 (hu) 2001-08-28
NO20005186D0 (no) 2000-10-16
AU3566499A (en) 1999-11-08
US20040033210A1 (en) 2004-02-19
ZA200005477B (en) 2001-11-20
AU758851B2 (en) 2003-04-03
NO20005186L (no) 2000-12-14
EP1071469A2 (en) 2001-01-31
JP2002512204A (ja) 2002-04-23
CZ20003817A3 (cs) 2002-08-14
RU2217168C2 (ru) 2003-11-27

Similar Documents

Publication Publication Date Title
PL343486A1 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
HUP0101352A3 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
HUP0300868A3 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
AU2002300464A1 (en) Apoliprotein A-I Agonist And Their Use To Treat Dyslipidemic Disorders
AU2002300785A1 (en) Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
IS5375A (is) KAY-nýstárlegt ónæmisprótín
NO972592L (no) Parasittformuleringer som kan påföres dermalt
AU4959199A (en) Chemokines as adjuvants of immune response
EP1110969A4 (en) INTERLEUKIN 18 BINDING PROTEIN
AU2003204353A1 (en) Methods and compositions for enhancing immune response and for the production of in vitro mabs
AU2901495A (en) 5-lipoxygenase-activating protein ii
AU3179999A (en) Methods to treat undesirable immune responses
EP1094081A4 (en) FUSIONED PROTEIN WITH DIRECT LINKAGE OF IL-6 TO IL-6 RECEPTOR
ID20291A (id) Asam-asam oksobutirat tersubstitusi sebagai penghamba-penghambat matriks metaloproteasa
AU2589399A (en) Human short-chain tnf-receptor family protein
PL346796A1 (en) Methods of downmodulating the immune response to therapeutic proteins
KR970053732U (ko) 용접기의 파워 커넥터
AU9484798A (en) Enhancement of mucosal antibody responses by interleukin-6
AU6019599A (en) Use of mcrp to enhance immune responses
AU2173799A (en) Expression of fusion proteins
AU4277899A (en) Tnfr-like protein with death domain
AU2002217895A1 (en) Inducing expression of heat shock proteins
AU1255999A (en) The nip3 family of proteins
AU2001245815A1 (en) Human immune response proteins
IT1294142B1 (it) Procedimento per la realizzazione di occhiali e occhiali ottenuti con detto procedimento